A Japanese health panel has approved national health insurance coverage for Sumitomo Pharma's Amchepry, an iPS cell-derived treatment for Parkinson’s disease. The move makes it the world's first commercialized medical product from iPS cells.
The approval came from a panel under the Ministry of Health, Labour and Welfare. It covers Sumitomo Pharma's Amchepry for use in treating Parkinson’s disease.
Amchepry is produced from induced pluripotent stem cells. The decision positions the product as the first such therapy to reach commercial status worldwide.
The panel's action clears the way for broader patient access through Japan's national health care system.
